Open Orphan PLC Rule 19.6(c) Confirmation (1811K)
31 Décembre 2020 - 8:00AM
UK Regulatory
TIDMORPH
RNS Number : 1811K
Open Orphan PLC
31 December 2020
THE FOLLOWING ANNOUNCEMENT IS BEING MADE PURSUANT TO THE
REQUIREMENTS OF RULE 19.6(C) OF THE CITY CODE ON TAKEOVERS AND
MERGERS, WHICH, INTER ALIA, REQUIRES A PARTY TO AN OFFER TO MAKE AN
ANNOUNCEMENT AT THE END OF A PERIOD OF 12 MONTHS FROM THE DATE ON
WHICH THE OFFER PERIOD ENDED CONFIRMING WHETHER IT HAS TAKEN, OR
NOT TAKEN, THE COURSE OF ACTION SET OUT IN ITS STATED
INTENTIONS.
Open Orphan plc
("Open Orphan" or the "Company")
RULE 19.6(c) CONFIRMATION WITH RESPECT TO STATED POST-OFFER
INTENTIONS WITH REGARD TO HVIVO PLC
Open Orphan plc (AIM: ORPH) announces that, further to the
completion of its recommended share-for-share exchange offer for
hVIVO plc which was declared unconditional as to acceptances on 31
December 2019, the Company has duly confirmed in writing to the
Panel on Takeovers And Mergers in the UK in accordance with the
requirements of Rule 19.6(c) of the City Code on Takeovers and
Mergers (the "Code") that the Company has complied with its
post-offer intention statements made pursuant to Rules 2.7(c)(iv)
and 24.2 of the Code, as originally detailed in the Company's Rule
2.7 announcement of 9 December 2019 and the offer document
published on 9 December 2019.
For further information please contact
Open Orphan plc +353 (0) 1 644 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser
and Joint Broker) +44 (0) 20 7614 5900
John Llewellyn-Lloyd / Benjamin Cryer
/ Dan Gee-Summons
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson/ Richard
Chambers
Davy (Euronext Growth Adviser and
Joint Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial +44 (0)20 7933 8780 or openorphan@walbrookpr.com
PR & IR)
Anna Dunphy / Paul McManus +44 (0)7876 741 001 / +44 (0)7980 541
893
About Open Orphan ( www.openorphan.com )
Open Orphan is a rapidly growing niche CRO pharmaceutical
services company which is the world leader in the testing of
vaccines and antivirals through the use of human challenge clinical
trials. Conducted from Europe's only 24-bedroom quarantine clinic
with onsite virology providing individually isolated rooms and
connected to our specialist laboratory facility. hVIVO's challenge
studies require healthy volunteers to take part, volunteers are
recruited through FluCamp, learn more at www.FluCamp.com . The
hVIVO facility offers highly specialised virology and immunology
laboratory services to support pre-clinical and clinical
respiratory drug, antiviral, and vaccine discovery and development.
Reliable laboratory analysis underpinned by scientific expertise is
essential when processing and analysing clinical samples. Robust
quality processes support our team of scientists in the delivery of
submission ready data.
The Company has a leading portfolio of 8 viral challenge study
models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD
viral challenge models. As announced in early March, Open Orphan is
rapidly advancing a number of Coronavirus challenge study models
and expects to be helping many COVID-19 vaccine development
companies to test their vaccines. No other company in the world has
such a portfolio, with only two competitors globally having 1
challenge study model each. hVIVO also works with companies in the
UK and Ireland to provide COVID-19 testing to staff to protect
staff and customers from a workplace COVID-19 outbreak through its
COVID Clear offering.
Open Orphan comprises of two commercial specialist CRO services
businesses, hVIVO and Venn Life Sciences and is also building out a
valuable data platform business. hVIVO has built up one of the
world's largest databases of infectious disease progression data
and we are populating our Open Orphan Health Data platform with
this historical hVIVO data. In our clinical trials going forward,
we are also planning to collect data on volunteer's via wearables
during clinical trials. Therefore, Open Orphan's data, which may
yield valuable digital biomarkers, could be one of the more
sought-after datasets by many of the large wearables /smart watch
wearables providers around the world. In June 2019, Open Orphan
acquired AIM-listed Venn Life Sciences Holdings plc in a reverse
take-over and in January 2020 it completed the merger with hVIVO
plc in January 2020. Venn is an integrated drug development
consultancy firm which offers CMC (chemistry, manufacturing and
controls), preclinical, Phase I & II clinical trials design and
execution. The merger with hVIVO created a European full pharma
services company broadening the Company's customer base and with
complementary specialist CRO services, widened the range of the
Company's service offerings.
If you are interested in being contacted and provided with
details about future COVID-19 human challenge study research,
please leave your contact details at www.UKCovidChallenge.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
OUPKKKBKQBDDQBN
(END) Dow Jones Newswires
December 31, 2020 02:00 ET (07:00 GMT)
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024